HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Callahan, R. J. Articles by Potsaid, M. S. Search for Related Content PubMed PubMed Citation Articles by Callahan, R. J. Articles by Potsaid, M. S.

Technetium-99m-human Serum Albumin: Evaluation of a Commercially Produced Kit

Massachusetts General Hospital, Boston, Massachusetts

Correspondence: For reprints contact: R. J. Callahan, Nuclear Medicine Div., Massachusetts General Hospital, Boston, Mass. 02114.

ABSTRACT

Results are reported on the use of a commercial kit for the labeling of human serum albumin with ^99mTc. One-hour blood levels obtained in 20 subjects undergoing gated cardiac imaging were found to be 46.0 ± 10.5% (s.d.) of the administered dose. The highest labeling efficiencies (94.2 ± 9.3%) were obtained when human serum albumin 25% (salt-poor) was used. Satisfactory nuclear cardiac ventriculographic images were obtained in patients receiving the radiopharmaceutical when the labeling efficiency was at least 85%. Occasional batches were milky in appearance, contained black particulate matter, were acidic, or contained a high percentage of unbound ^99mTc activity. Although this kit makes ^99mTc-human serum albumin accessible to most nuclear medicine facilities for general clinical use, an active quality control program is required prior to use in patients.

FOOTNOTES

^* Present address: College of Pharmacy, The University of Michigan, Ann Arbor, Mich. 48104.